GeoVax Labs, Inc. to Present at the 12th Annual BIO CEO & Investor Conference

ATLANTA, Feb. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a corporate update at the 12th Annual BIO CEO & Investor Conference.  The presentation will take place at 1:00 p.m. Eastern Time on February 9, 2010 at the Waldorf Astoria Hotel in New York City.

The presentation will be webcast live and may be accessed by visiting the company's homepage or "Investors" tab at www.geovax.com. A replay of the webcast will be available on the company's website for 90 days.

Dr. McNally commented, "This Conference offers GeoVax many opportunities including updating attendees on our progress on both preventative and therapeutic human vaccine trial fronts, and meeting with potential partners, investors and analysts.  We look forward to the opportunity."

About BIO (Biotechnology Industry Organization) CEO & Investor Conference

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.  BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies.  BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.

About HIV/AIDS

AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation.  33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year.  Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus.  Every 9 1/2 minutes, someone in the US is infected with AIDS. Globally, HIV is the top killer among women of reproductive age.

HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world.  Clade B is the predominant subtype in North America.  Globally, most infections involve subtypes AG, B, and C. In 2008, antiretroviral treatment in low and middle income countries was restricted to about 3 million people. In the United States, about 50% of those who are infected are estimated to be on drug treatment.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.  GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications.  GeoVax AIDS vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Chief Scientific Officer, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington.  The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines.  Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $18 million IPCAVD grant awarded in late 2007.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED